The elderly population have and increased risk of loss of both muscle mass and function and is therefore recommended a higher protein intake than the healthy adult population. These age-related changes in muscle function may be explained by chronic low-grade inflammation and insulin resistance. Despite the recommendation of a higher protein intake, little is known about how different protein sources may affect the metabolic health in this population. Analysis of amino acid composition show that fish can be a good protein source for humans. Many fish species are today used as feed ingredients, rather than a protein source for humans. A few studies conducted in humans and rats show that proteins from fish may improve glucose tolerance, reduce inflammation and improve lipid metabolism, indicating that proteins from fish may not only serve as a valuable nutrient but could also hold specific health promoting properties. The present study will investigate the effects of a protein hydrolysate from blue whiting, a fish species normally used to produce fish meal for aquaculture industry, on glucose homeostasis, inflammation and serum lipids in elderly nursing home residents.
Participants receive 6g per day of protein hydrolysate from blue whiting as protein powder mixed with a non-caloric juice for 6 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
24
Dietary Supplement: Blue whiting protein hydrolysate 6g protein per day for 6wk
Control group will receive non-caloric juice without protein supplementation
Participant compliance
Investigate the participant compliance based daily registrations by nursing home staff
Time frame: 6 weeks
Participant dropout rate
Number of participants that completed the intervention period
Time frame: 6 weeks
Glucose regulation
Glucose concentration will be measured in fasting serum
Time frame: 6 weeks
Insulin
Insulin will be measured in fasting serum/plasma
Time frame: 6 weeks
C-reactive protein in serum
C-reactive protein (a marker of inflammation) will be analysed in fasting serum
Time frame: 6 weeks
Interleukin-6 in serum
Interleukin-6 (a marker of inflammation) will be analysed in fasting serum
Time frame: 6 weeks
Monocyte chemoattractant protein-1 in serum
Monocyte chemoattractant protein-1 (a marker of inflammation) will be analysed in fasting serum
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.